Novartis UK, pharmaceutical manufacturing isn't just a business, it's an art. Novartis UK is the British affiliate of Swiss-based Novartis AG, its operations include Novartis Pharmaceuticals UK, the prescription drug production arm that makes such products as tumor inhibitor Glivec and pain reliever Voltaren. Its Vaccine and Diagnostics division operates an influenza vaccine manufacturing facility. The company's Consumer Health division develops and manufactures such OTC products as Savlon antiseptic and Otrivin decongestant. Consumer Health also manufactures and markets drugs for companion animals and livestock, and includes contact lens maker CIBA Vision (UK).

Genzyme Diagnostics was founded in 1981. A division of Genzyme, it develops, manufactures, and distributes "in vitro" diagnostic products, including point-of-care tests. The division also produces the raw materials (such as enzymes and antibodies used in tests for diabetes, cholesterol, and pancreatitis) and chemical reagents used by other diagnostic test manufacturers to make their own diagnostic tests. The company's point-of-care products (tests administered at a patient's bedside) include tests for strep A, mononucleosis, and bacterial vaginitis; it also offers several different pregnancy tests.

MEDA PHARMACEUTICALS INC. is the U.S. subsidiary of Meda AB. Meda Pharmaceuticals specializes in respiratory, allergy, central nervous system, and cough-cold products. MEDA AB is an international specialty pharma company that concentrates on marketing and market-adapted product development. Acquisitions and long-term partnerships are fundamental factors that drive the company’s strategy. Meda is represented with own organizations in 26 countries and with more than 1,500 employees within marketing and sales. Meda’s products are sold in approximately 120 countries world-wide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange.

Allermed Laboratories, Inc. company was founded in 1971. Allermed Laboratories knows that in the case of allergies, a little bit of what caused the problem can be the solution. The company manufactures allergenic extracts, such as plant pollens, insects, fish and shellfish, and various foods, used to both diagnose and treat allergic conditions. The company is also developing additional skin tests for allergies, as well new tests to detect Leishmania parasite infections and exposure to the fungus Coccidioides immitis. Other products include empty test vials, vial trays, diluents, and extract mixing syringes. Outside of allergists' offices, the company provides environmental testing kits to detect mold contamination of buildings.

Upsher-Smith Laboratories, Inc. was founded in 1919 and is headquartered in Minneapolis, Minnesota with a facility in Denver, Colorado. Upsher-Smith Laboratories, Inc., a pharmaceutical company, engages in developing, manufacturing, commercializing, marketing, and distributing prescription and over-the-counter products. It offers drugs for cardiology, women's health, dermatology, neurology, and epilepsy and Parkinson's diseases. The company also provides prenatal vitamins. It serves patients, physicians, pharmacists, and healthcare organizations.

Tridelta specialises in the development, manufacturing and marketing of diagnostic products for the animal health care industry. The company has commercialised five technologies to date with its "PHASE" range of Acute Phase Protein Assays, which are indicators of the presence of an inflammatory reaction, detected in the blood before the animal shows any physical signs of ill health. Species of specific interest include: cattle, horses, sheep, cats, dogs, pigs and rodents.

Adnexus Therapeutics, Inc. engages in the discovery, development, and commercialization of Adnectins biologics/medicines in the United States. The company’s product candidates include Angiocept/CT-322, an anti-angiogenesis agent for treating cancer that blocks the VEGFR-2 pathway; and other Adnectin therapies for the treatment of oncology, immunology, and cardiovascular diseases. Adnexus Therapeutics, Inc. was formerly known as Compound Therapeutics, Inc. and changed its name to Adnexus Therapeutics, Inc. in June 2006. The company was founded in 2002 and is headquartered in Waltham, Massachusetts. As of October 19, 2007, Adnexus Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Co.

Ceragenix Pharmaceuticals was founded in 2002 is based in Denver, Colorado. Ceragenix Pharmaceuticals, Inc. operates as a medical device company focusing on infectious diseases and dermatology in the United States. The company has two base technology platforms, which include Ceragenins for the treatment of infectious disease; and Barrier Repair for the treatment of dermatological disorders, including atopic dermatitis, neonatal skin disorders, and others. Its Ceragenin compounds are active against a range of gram positive and negative bacteria. The company uses its Ceragenin technology to formulate Cerashield antimicrobial coatings for medical devices. Its Barrier Repair technology is the platform for the development of two prescription topical creams, including EpiCeram, a prescription product for the treatment of dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses, including eczema, irritant contact dermatitis, and radiation dermatitis; and NeoCeram, a pediatric barrier repair cream intended to create a skin barrier in premature infants and neonates.

Merz may be a little sterile, but it aims to take care of every part of the functioning human organism. Merz primarily makes pharmaceuticals, focusing on therapies for central nervous system and liver metabolism. The company also offers several OTC products, including cold remedies, skin care products, and vitamin supplements under the brand names tetesept and Merz Special. Subsidiaries include Merz Pharmaceuticals, Merz Consumer Care, Merz Dental, maker of dental equipment and artificial teeth, and Merz & Krell, which produces Senator-brand writing instruments.

Prana Biotechnology Limited (Prana) is a development-stage company at an early stage in the development of its pharmaceutical products that are designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. Other potential applications for the Company’s therapies include Huntington’s disease, Parkinson’s disease, certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease) and age-related cataracts. The Company has two wholly owned subsidiaries, Prana Biotechnology Inc. and Prana Biotechnology UK Limited. Prana’s activities are focused within Australia and cover research into Alzheimer’s disease and other age-related degenerative disorders.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.